NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
Priority Review
CIMDUO (lamivudine and tenofovir disoproxil fumarate) by Viatris is nucleoside reverse transcriptase inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult. First approved in 2018.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMDUO is a fixed-dose combination of lamivudine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. The drug works by inhibiting reverse transcriptase, the enzyme HIV uses to replicate, and must be used in combination with other antiretroviral agents. It is administered as an oral tablet.
$0.274MPart D
PeakProduct is in peak lifecycle stage with modest Medicare Part D penetration; team size likely stable with focus on retention and managed care optimization rather than aggressive expansion.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Career Relevance
Working on CIMDUO offers career stability within an established, mature product in a well-defined therapeutic area with a defined patient population. Roles focus primarily on commercial execution, market access navigation, and competitive positioning rather than innovation or launch dynamics.
Worked on CIMDUO at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.